



BAISHIDENG PUBLISHING GROUP INC

8226 Regency Drive, Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

http://www.wjgnet.com

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Nephrology

ESPS manuscript NO: 23152

Title: Stop chronic kidney disease progression: Time is approaching

Reviewer's code: 00351316

Reviewer's country: Spain

Science editor: Jin-Xin Kong

Date sent for review: 2015-10-27 17:19

Date reviewed: 2015-12-21 15:16

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> [Y] Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> [] High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> [] Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	[Y] No	<input type="checkbox"/> [] Minor revision
		BPG Search:	<input type="checkbox"/> [] Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Figure 1 does not give relevant information, and it can be deleted. Including a couple of tables in order to summarize the most relevant information about standard of care management and novel therapeutic interventions would be interesting.



ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Nephrology

ESPS manuscript NO: 23152

Title: Stop chronic kidney disease progression: Time is approaching

Reviewer's code: 01209905

Reviewer's country: Japan

Science editor: Jin-Xin Kong

Date sent for review: 2015-10-27 17:19

Date reviewed: 2015-12-22 11:03

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This review article on the progression of CKD is well written in which the latest knowledge was gathered and well organized. There are still to be added. 1. Bardoxolone methyl has been reported to have a renoprotective effect on diabetic nephropathy through activation of the Nrf2-Keap1 signaling pathway, although a phase 3 trial (BEACON trial) was terminated due to excessive cardiovascular disease and especially heart failure in patients allocated to bardoxolone methyl. However, development of this drug is continuing in other territories, and a phase 2 study in pulmonary arterial hypertension is presently conducting. Recently, a phase 2 study in diabetic nephropathy has been re-started in Japan. It is suggested to describe something about bardoxolone methyl in this review. 2. The authors described the involvement of hyperphosphatemia in the faster progression of CKD. In this points, a possibility of calciprotein particle (CPP) as a true culprit of phosphorus woes has been reported. It is suggested to describe about CPP in this review.